


### Amendments to the Claims

The following Listing of Claims will replace all prior versions and listings of claims in the above-referenced application.

#### Listing of Claims:

Claims 1-144. (Canceled)

144. (Currently Amended) A pharmaceutical composition for delivering a therapeutically effective amount of a compound to a mammal, the pharmaceutical composition comprising:  
an amount of a compound [and a therapeutically acceptable carrier, wherein the compound has] having the structure:



wherein R is [hydrogen or] methyl; and

a pharmaceutically acceptable carrier selected from the group consisting of glycols, oils, and alcohols,

wherein the amount of the compound in the carrier is sufficient for the composition to deliver to the mammal between about 0.001 mg [to] and about [40] 0.6 mg compound [pre] per kg body weight.

145. (Canceled)

Page 2 of 10

USSN 09/874,514  
3574523\_3.DOC

Attorney Docket No.: 2003080-0082  
Client Ref. No.: SK-744-US/CON3


146. (Canceled)

147. (Canceled) The pharmaceutical composition of [any one of claims] claim 144[-146], wherein the therapeutically effective amount is an amount sufficient to deliver about [0.01] 0.001 mg to about [40] 0.6 mg compound per kg body weight.

148. (Currently Amended) The pharmaceutical composition of [any one of claims] claim 144[-146], wherein the therapeutically effective amount is an amount sufficient to deliver about [0.001] 0.01 mg to about [25] 0.6 mg compound per kg body weight.

149. (Canceled)

150. (Currently Amended) A method of treating cancer in a subject comprising:  
administering to the subject in need thereof [a therapeutically effective amount] an average daily dose of a compound having the structure:



wherein R [is hydrogen or] methyl[]; and

wherein the therapeutically effective amount of the compound is an amount between about 0.001 mg to about 40 mg], that is between about 0.001 and 0.6 mg of compound per kilogram of the subject's body weight.

151. (Canceled)

152. (Canceled)

153. (Canceled)


154. (Currently Amended) The method of [any one of claims] claim 150[-152], wherein the [therapeutically effective amount is an amount sufficient to deliver] average daily dose is within the range of about [0.001] 0.01 mg to about [25] 0.6 mg compound per kg body weight.

155. (Canceled)

156. (Canceled)

157. (Canceled).

158. (Currently Amended) A method of inhibiting growth of a tumor in an animal comprising:  
administering to an animal that has a tumor an amount of a composition comprising a  
compound having the structure:



Page 4 of 10

USSN 09/874,514  
3574523\_3.DOC

Attorney Docket No.: 2003080-0082  
Client Ref. No.: SK-744-US/CON3

wherein R is [hydrogen or] methyl;

wherein the amount [being] is [effective to inhibit growth of the tumor without administration of the composition killing the animal; and

wherein the amount of the composition is an amount] sufficient to deliver an average daily dose of the compound that is within the range of about 0.001 to 0.06 mg [to about 40 mg epothilone] of the compound per kilogram body weight.

159. (Canceled)

160. (Canceled)

161. (New) The method of claim 150 or claim 158, wherein the step of administering comprises administering individual doses not more frequently than once daily.

162. (New) The method of claim 150 or claim 158, wherein the step of administering comprises interrupting individual dose administrations with at least one day of rest.

163. (New) The method of claim 150 or claim 158, wherein the step of administering comprises interrupting individual dose administrations with at least three days of rest.

164. (New) The method of claim 150 or claim 158, wherein the step of administering comprises administering over a period of at least about 6 days.

165. (New) The method of claim 150 or claim 158, wherein the step of administering comprises administering to an animal that has a multidrug resistant tumor.

166. (New) The method of claim 150 or claim 158, wherein the step of administering according to a schedule sufficient to achieve at least about 16% tumor inhibition.

167. (New) The composition of claim 144, wherein the composition is formulated for parenteral delivery.

168. (New) The composition of claim 144, wherein the composition is formulated for oral delivery.

169. (New) The composition of claim 144, wherein the composition comprises an emulsion.

170. (New) The composition of claim 144, wherein the composition comprises an aqueous suspension.